[Long-term prophylaxis of thromboembolism and fraxiparin].
23 consecutive patients were enrolled in the study, 21 after deep venous thrombosis, in 40% complicated by pulmonary embolism, and 2 with mechanical prosthetic heart valves with contraindications to oral anticoagulation. All of them received fraxiparine s.c. in doses of 7500 U anti-Xa daily, from at least 9 to 24 months. Fraxiparine was well tolerated. Re-thrombosis or signs of pulmonary embolisation as well as bleeding complications have not been observed. Long-term subcutaneous administration of fraxiparine is an effective and safe alternative for the prophylaxis of thromboembolism in cases with contraindication to oral anticoagulation, although the danger of osteoporosis should be considered.
Czestochowska
E
E
IV Klinika Chorób Wewnetrznych, Instytutu Chorób Wewnetrznych Akademii Medycznej w Gdańs-ku.
Arasimowicz
P
P
D000925:Anticoagulants / Q000627:therapeutic use*; D000075202:Contraindications; D004334:Drug Administration Schedule; D006350:Heart Valve Prosthesis; D006801:Humans; D017762:Nadroparin / Q000627:therapeutic use*; D011655:Pulmonary Embolism / Q000150:complications; D013923:Thromboembolism / Q000150:complications / Q000517:prevention & control*
D000925:Anticoagulants; D017762:Nadroparin
Długotrwała profilaktyka przeciwzakrzepowa fraksyparyna.